Literature DB >> 16821216

[Markers of malignancy in pheochromocytomas].

Stanisław Sporny1, Jacek Musiał.   

Abstract

A pheochromocytoma is a neoplasm composed of cells which synthesize and release catecholamines. These tumors produce the hypertension which can be cured with surgical excision of the lesion. The pathological picture of pheochromocytomas is varied and nothing but the presence of metastases can determine aggressiveness of this neoplasm. Current studies try to look for other biological markers which can separate malignant tumors before they metastasize. It allows to target with more effective therapy. Many studies analyze details of microscopic features of these tumors, immunohistochemical markers and molecular disorders. It seems that the most important factor in estimation of aggressiveness of pheochromocytomas is PASS scale. The detection of high expression of telomerase and hTERT and high proliferative activity, measured by immunohistochemistry with the MIB-1 antibody supports most strongly biological malignancy of pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16821216

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  3 in total

1.  A spontaneous paraganglioma-pheochromocytoma syndrome.

Authors:  Sadegh Toutounchi; Ryszard Pogorzelski; Maciej Siński; Izabela Loń; Lukasz Zapała; Patryk Fiszer; Ewa Krajewska; Maciej Skórski
Journal:  Cent European J Urol       Date:  2014-01-27

2.  The local spread of pheochromocytoma after adrenalectomy with a rupture of the tumor capsule at the time of the surgery.

Authors:  Ryszard Pogorzelski; Sadegh Toutounchi; Patryk Fiszer; Ewa Krajewska; Izabela Łoń; Łukasz Zapała; Maciej Skórski
Journal:  Open Med (Wars)       Date:  2015-08-04

3.  From arterial hypertension complications to von Hippel-Lindau syndrome diagnosis.

Authors:  Sylwia Kozaczuk; Iwona Ben-Skowronek
Journal:  Ital J Pediatr       Date:  2015-08-13       Impact factor: 2.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.